US-based global healthcare company Viatris Inc (Nasdaq:VTRS) reported on Friday that a randomised, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.

Viatris chief R&D officer Philippe Martin said: "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 programme, which may include revising the planned additional Phase 3 study."

The company says that it is focused on delivering novel therapies like Tyrvaya and RYZUMVI, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions. In June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. The company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia.

The MR-139 3001 Phase 3 trial consisted of a randomised, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomised to receive either MR-139 or placebo, self-administered to the eyelids twice daily, treated and observed over 12 weeks.